How Australia’s health system is failing patients by prioritising process and cost control over timely access to treatment, forcing more to rely on compassionate access programs. HTA processes are slow, often dehumanising, and used by the gover...

In this episode, we examine funding uncertainty for genomic profiling through OMICO, structural tensions within the PBS and pharmaceutical supply chain, and broader concerns about how political and financial incentives shape health policy and b...

Australia’s system for deciding whether new health technologies are funded is too focused on contested models and not enough on real people and their needs. The lack of human consideration leads to long delays, avoidable suffering, and sometime...

Reflect on  Susan Ley’s legacy as a former health minister, especially the 2015 PBS Access and Sustainability Package. She was treated rudely and unfairly, and that meaningful ecosystem reform has since stalled. Critique Senate Estimates, ...

Mark Butler’s four 'pillars' on medicines policy and the argument that Australia prioritises low prices over preventing shortages and ensuring access. Do we need smarter, targeted incentives to address shortages that often reflect global challe...